InTouch and ASCO Announce New Cancer Information Feature

Publication
Article
OncologyONCOLOGY Vol 16 No 4
Volume 16
Issue 4

InTouch magazine, the Good Health Guide to Cancer Prevention and Treatment, has joined forces with the American Society of Clinical Oncology (ASCO).

InTouch magazine, the Good Health Guide toCancer Prevention and Treatment, has joined forces with the American Society ofClinical Oncology (ASCO). Beginning with the May 2002 issue of InTouch, ASCOwill contribute a regular page to the magazine, which is published six times ayear.

"InTouch is committed to providing cancer patients andtheir families with comprehensive information on cancer prevention and treatmentoptions," said Randi Londer Gould, managing editor of InTouch."Teaming with ASCO adds strength to our efforts and broadens the scope ofthe resources we provide for our readers."

The new feature combines the oncologist-approved cancerinformation contained in InTouch with the latest news from ASCO. The debutcolumn will highlight ASCO’s patient information materials and onlineresources, including their new cancer information website, People Living WithCancer, scheduled to launch in May.

"ASCO is all about taking care of patients," saidLarry Norton, MD, ASCO President. "ASCO serves the people who treat peoplewith cancer. This collaboration with InTouch, which shares our commitment toenhancing patient-physician communication, will enable ASCO to reach even morepatients with the information they need to make informed decisions about theirhealth care."

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Related Content